Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spasma (also known as Spasma Syrup) is a proprietary Ayurvedic herbal formulation developed and marketed by Charak Pharma. It is indicated as a natural bronchodilator, anti-inflammatory, and immunomodulator for the management of respiratory disorders, including bronchial asthma, bronchitis, and persistent paroxysmal cough. The formulation contains a synergistic blend of traditional Ayurvedic herbs, primarily *Adhatoda vasica* (Vasa), *Curcuma longa* (Haridra/Turmeric), and *Solanum xanthocarpum* (Kantakari), along with ammonium chloride. These ingredients work together to relax bronchial smooth muscle, reduce airway inflammation, exert anti-allergic effects, and promote the expectoration of viscid mucus, thereby improving breathing and reducing the frequency and severity of asthmatic attacks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Spasma.